IBM vs. LLY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at IBM and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | IBM | LLY |
|---|---|---|
| Company Name | International Business Machines Corporation | Eli Lilly and Company |
| Country | United States | United States |
| GICS Sector | Information Technology | Health Care |
| GICS Industry | IT Services | Pharmaceuticals |
| Market Capitalization | 225.94 billion USD | 632.40 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 1962 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of IBM and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | IBM | LLY |
|---|---|---|
| 5-Day Price Return | 2.29% | 3.07% |
| 13-Week Price Return | -9.63% | -6.58% |
| 26-Week Price Return | -6.42% | -19.09% |
| 52-Week Price Return | 24.56% | -23.47% |
| Month-to-Date Return | -4.19% | -4.68% |
| Year-to-Date Return | 10.34% | -8.62% |
| 10-Day Avg. Volume | 5.60M | 9.65M |
| 3-Month Avg. Volume | 4.60M | 4.51M |
| 3-Month Volatility | 24.47% | 40.54% |
| Beta | 0.69 | 0.46 |
Profitability
Return on Equity (TTM)
IBM
21.99%
IT Services Industry
- Max
- 29.51%
- Q3
- 16.98%
- Median
- 13.47%
- Q1
- 7.93%
- Min
- -3.97%
In the upper quartile for the IT Services industry, IBM’s Return on Equity of 21.99% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
IBM
9.11%
IT Services Industry
- Max
- 19.82%
- Q3
- 11.49%
- Median
- 6.67%
- Q1
- 3.61%
- Min
- -4.62%
IBM’s Net Profit Margin of 9.11% is aligned with the median group of its peers in the IT Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
IBM
9.77%
IT Services Industry
- Max
- 21.69%
- Q3
- 14.50%
- Median
- 10.06%
- Q1
- 6.98%
- Min
- 0.06%
IBM’s Operating Profit Margin of 9.77% is around the midpoint for the IT Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | IBM | LLY |
|---|---|---|
| Return on Equity (TTM) | 21.99% | 88.36% |
| Return on Assets (TTM) | 4.12% | 16.02% |
| Net Profit Margin (TTM) | 9.11% | 25.91% |
| Operating Profit Margin (TTM) | 9.77% | 32.37% |
| Gross Profit Margin (TTM) | 57.57% | 82.64% |
Financial Strength
Current Ratio (MRQ)
IBM
0.91
IT Services Industry
- Max
- 2.42
- Q3
- 1.81
- Median
- 1.47
- Q1
- 1.09
- Min
- 0.44
IBM’s Current Ratio of 0.91 falls into the lower quartile for the IT Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
IBM
2.33
IT Services Industry
- Max
- 2.33
- Q3
- 1.17
- Median
- 0.54
- Q1
- 0.15
- Min
- 0.00
IBM’s leverage is in the upper quartile of the IT Services industry, with a Debt-to-Equity Ratio of 2.33. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
IBM
45.57
IT Services Industry
- Max
- 144.50
- Q3
- 84.49
- Median
- 13.76
- Q1
- 2.59
- Min
- -28.13
IBM’s Interest Coverage Ratio of 45.57 is positioned comfortably within the norm for the IT Services industry, indicating a standard and healthy capacity to cover its interest payments.
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | IBM | LLY |
|---|---|---|
| Current Ratio (MRQ) | 0.91 | 1.28 |
| Quick Ratio (MRQ) | 0.80 | 0.53 |
| Debt-to-Equity Ratio (MRQ) | 2.33 | 2.18 |
| Interest Coverage Ratio (TTM) | 45.57 | 20.36 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
IBM
2.76%
IT Services Industry
- Max
- 2.80%
- Q3
- 1.74%
- Median
- 0.62%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.76%, IBM offers a more attractive income stream than most of its peers in the IT Services industry, signaling a strong commitment to shareholder returns.
LLY
0.77%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
IBM
75.57%
IT Services Industry
- Max
- 147.75%
- Q3
- 63.58%
- Median
- 24.63%
- Q1
- 0.00%
- Min
- 0.00%
IBM’s Dividend Payout Ratio of 75.57% is in the upper quartile for the IT Services industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | IBM | LLY |
|---|---|---|
| Dividend Yield (TTM) | 2.76% | 0.77% |
| Dividend Payout Ratio (TTM) | 75.57% | 36.46% |
Valuation
Price-to-Earnings Ratio (TTM)
IBM
38.56
IT Services Industry
- Max
- 41.55
- Q3
- 31.54
- Median
- 23.25
- Q1
- 18.12
- Min
- 6.57
A P/E Ratio of 38.56 places IBM in the upper quartile for the IT Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
LLY
47.48
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
IBM
3.51
IT Services Industry
- Max
- 6.61
- Q3
- 4.37
- Median
- 2.02
- Q1
- 1.20
- Min
- 0.19
IBM’s P/S Ratio of 3.51 aligns with the market consensus for the IT Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
LLY
12.30
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
IBM
9.96
IT Services Industry
- Max
- 11.19
- Q3
- 6.38
- Median
- 3.47
- Q1
- 2.31
- Min
- 0.96
IBM’s P/B Ratio of 9.96 is in the upper tier for the IT Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | IBM | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 38.56 | 47.48 |
| Price-to-Sales Ratio (TTM) | 3.51 | 12.30 |
| Price-to-Book Ratio (MRQ) | 9.96 | 40.43 |
| Price-to-Free Cash Flow Ratio (TTM) | 19.13 | 326.03 |